CA2501220A1 - Vaccines against west nile virus - Google Patents

Vaccines against west nile virus Download PDF

Info

Publication number
CA2501220A1
CA2501220A1 CA002501220A CA2501220A CA2501220A1 CA 2501220 A1 CA2501220 A1 CA 2501220A1 CA 002501220 A CA002501220 A CA 002501220A CA 2501220 A CA2501220 A CA 2501220A CA 2501220 A1 CA2501220 A1 CA 2501220A1
Authority
CA
Canada
Prior art keywords
west nile
cell
nile virus
lineage
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002501220A
Other languages
French (fr)
Other versions
CA2501220C (en
Inventor
Alphonsus Gerardus Cornelis Maria Uytdehaag
Govert Johan Schouten
Jaap Goudsmit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holland B.V.
Alphonsus Gerardus Cornelis Maria Uytdehaag
Govert Johan Schouten
Jaap Goudsmit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland B.V., Alphonsus Gerardus Cornelis Maria Uytdehaag, Govert Johan Schouten, Jaap Goudsmit filed Critical Crucell Holland B.V.
Publication of CA2501220A1 publication Critical patent/CA2501220A1/en
Application granted granted Critical
Publication of CA2501220C publication Critical patent/CA2501220C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived there from, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (El) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.

Claims (13)

1. A method for producing an inactivated West Nile Virus comprising the steps of:
a) infecting an adenovirus E1-immortalised cell with a West Nile Virus;
b) culturing the cell obtained in step a) in a suitable medium under conditions that cause said virus to replicate in the cell;
c) optionally harvesting the produced West Nile Virus; and d) inactivating the produced West Nile Virus.
2. A method according to claim 1, wherein said adenovirus E1-immortalised cell is derived from a non-tumorous human cell.
3. A method according to claim 1 or 2, wherein said adenovirus E1-immortalised cell is derived from a retinoblast, a kidney cell or an amniocyte.
4. A method according to claim 1 or 2, wherein said adenovirus E1-immortalised cell is derived from an embryonic retinoblast.
5. A method according to claim 4, wherein said cell is a cell as deposited under ECACC no. 96022940, or a derivative thereof.
6. A method according to any one of claims 1-5, wherein said West Nile Virus is lineage II strain West Nile B956, lineage II strain Madagascar 1978, lineage II
strain Cyprus 1968, lineage I strain Kunjin 1960, lineage T strain Kunjin 1991, lineage I strain Goose Israel 1998 or lineage I strain New York 1999.
7. A method according to any one of claims 1-5, wherein said West Nile Virus is a lineage II strain selected from the group consisting of: Kenya, Uganda, Senegal 1990, Uganda 1937, Uganda 1959, Central African Republic 1972a, Central African Republic 1972b, Central African Republic 1983, Madagascar 1986 and Madagascar 1988.
8. A method according to any one of claims 1-7, wherein said West Nile Virus is applied in a multiplicity of infection ranging from 5 to 5×10 -7 plaque forming units per cell.
9. A method according to any one of claims 1-8, wherein said inactivation step is performed before the step of harvesting said produced West Nile Virus.
10. A method according to any one of claims 1-9, wherein said produced West Nile Virus is inactivated by formaldehyde.
1l. A method according to any one of claims 1-10, further comprising the steps of:
a) disrupting the produced West Nile Virus; and b) purifying one or more antigenic components of said West Nile Virus, disrupted in the previous step.
12. A human cell having a sequence encoding at least an E1A gene product of an adenovirus in its genome and having a nucleic acid coding for a West Nile Virus.
13. A human cell according to claim 12, wherein said human cell is a derivative of a cell as deposited under ECACC no. 96022940, or a derivative thereof.
CA2501220A 2002-11-08 2003-11-07 Vaccines against west nile virus Expired - Fee Related CA2501220C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NLPCT/NL02/00718 2002-11-08
NLPCT/NL02/00718 2002-11-08
EPPCT/EP03/50129 2003-04-28
EPPCT/EP03/50129 2003-04-28
PCT/EP2003/050806 WO2004042042A1 (en) 2002-11-08 2003-11-07 Vaccines against west nile virus

Publications (2)

Publication Number Publication Date
CA2501220A1 true CA2501220A1 (en) 2004-05-21
CA2501220C CA2501220C (en) 2012-01-17

Family

ID=32313778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2501220A Expired - Fee Related CA2501220C (en) 2002-11-08 2003-11-07 Vaccines against west nile virus

Country Status (7)

Country Link
AT (1) ATE453708T1 (en)
AU (1) AU2003298277B2 (en)
CA (1) CA2501220C (en)
DE (1) DE60330795D1 (en)
IL (1) IL168374A (en)
NZ (1) NZ538808A (en)
WO (1) WO2004042042A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957200C (en) 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
BRPI0611581B1 (en) * 2005-06-24 2021-08-03 Intervet International B.V. INACTIVATED CHIMERIC FLAVIVIRUS, IMMUNOGENIC COMPOSITION, AND, VACCINE
ATE463559T1 (en) * 2005-07-22 2010-04-15 Crucell Holland Bv CELL LINE FOR THE PRODUCTION OF CORONAVIRUSES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US20030148261A1 (en) * 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides

Also Published As

Publication number Publication date
AU2003298277B2 (en) 2009-01-22
NZ538808A (en) 2008-03-28
ATE453708T1 (en) 2010-01-15
AU2003298277A1 (en) 2004-06-07
CA2501220C (en) 2012-01-17
IL168374A (en) 2010-11-30
WO2004042042A1 (en) 2004-05-21
DE60330795D1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
CA2410948C (en) Method for the purification of alphavirus replicon particles
Duarte et al. Many-trillionfold amplification of single RNA virus particles fails to overcome the Muller's ratchet effect
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
HK1078777A1 (en) Modified vaccinia virus ankara for the vaccination of neonates
NO20051175L (en) Process for the preparation of primary cells and for amplification of viruses under serum-free conditions
CA2415990A1 (en) Method for producing biologicals in protein-free culture
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
US20190292231A1 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
YU37502A (en) Infectious clones
JP2011078424A (en) Method for virus propagation
WO1997005255A3 (en) Helper viruses for preparing recombinant viral vectors
GB2209764A (en) Recombinant vaccinia virus
US11534417B2 (en) Enhanced expression of RNA vectors
CA2501220A1 (en) Vaccines against west nile virus
Netter et al. Nucleotide sequence stability of the genome of hepatitis delta virus
WO2020034584A1 (en) Bhk21 cell population innate immune system of which is remodeled and application thereof in enhancing cell clone virus proliferation
EP0326127A3 (en) Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same
JP2006526393A5 (en)
AU2002212555A1 (en) Yeast derived vaccine against ipnv
Osterrieder et al. Attenuation of viruses by large-scale recoding of their genomes: the selection is always biased
NO20073809L (en) Virus preparations and methods
EP2647645B1 (en) Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom
JP6708636B2 (en) Method for promoting viral infection and enhancing production using a cell line in which the function of Bst2 gene is lost
NO20005482D0 (en) Recombinant virus expressing foreign DNA encoding Felin CD80, Felin CTLA-4 or Felin CD86 and use thereof
WO2000049166A3 (en) Production of helper dependent adenovirus vectors based on use of endonucleases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131107